Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Deuterabenazine

The articles shown below are all about the Deuterabenazine, through these related articles, you can get relevant information, notes in use, or latest trends about the Deuterabenazine. We hope these news will give you the help you need. And if these Deuterabenazine articles can't solve your needs, you can contact us for relevant information.
  • Drug Patent & Exclusivity Expiration Report - Week of Dec 23 2024

    Drug Patent & Exclusivity Expiration Report - Week of Dec 23 2024

    2024-12-23

    This week, there are 4 drugs in the patent and exclusivity list. They are: - STEMLINE THERAPEUTICS INC's ORSERDU, containing active ingredient ELACESTRANT DIHYDROCHLORIDE - ABBVIE INC's UBRELVY, containing active ingredient UBROGEPANT - TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC's AUSTEDO, containing active ingredient DEUTETRABENAZINE - OTSUKA PHARMACEUTICAL CO LTD's REXULTI, containing active ingredient BREXPIPRAZOLE Read More